Amarin Corporation PLC (NASDAQ: AMRN) is a rapidly growing, innovative pharmaceutical company that purposefully focuses on the development and commercialization of therapeutics to improve cardiovascular health. With its corporate headquarters in Dublin, Ireland, and its R&D center in New Jersey, USA, Amarin has a truly international perspective.
A significant part of the company’s success centers around its lead product, Vascepa (icosapent ethyl). Vascepa is the first and only prescription treatment approved by the FDA comprised solely of the active ingredient, icosapent ethyl, a unique form of eicosapentaenoic acid. The product is used alongside a low-fat and low-cholesterol diet, to lower high levels of triglycerides (fats) in adults, thus helping to reduce the potential risks of cardiovascular diseases.
This revolutionary drug is derived from fish oil yet is distinctly different as it is not a mixture of dietary supplement molecules but a single molecule therapeutic agent. Vascepa has also shown to have no relevant negative drug-drug interaction when administered with statins (cholesterol-reducing medications). This makes it an effective treatment in patients who are already taking cholesterol-lowering medications but need additional help in combating high triglyceride levels.
Amarin Corporation’s commitment to scientific rigor has led to groundbreaking results that have propelled this leading edge company into the forefront of cardiovascular health. It was backed by more than a decade of scientific research, including the result of REDUCE-IT cardiovascular outcomes study, the research which provided the basis for Vascepa's initial approval by the FDA.
Amarin has positioned itself worldwide by establishing strategic collaborations with other medical and commercial entities to distribute Vascepa globally. They have partners in Canada, China, the Middle East and North Africa, thereby securing Vascepa's accessibility to physicians and patients in need outside the United States.
The company is also committed to the continuous evaluation of Vascepa’s clinical effects on other conditions such as diabetes, inflammation, and others. As of today, it has several ongoing clinical trials, revealing the company’s commitment to scientific research and innovation.
Despite facing some recent challenges concerning patent litigation over Vascepa, the future for Amarin remains bright. The company’s mission, ‘Science Transforming Life,’ is an accurate summation of its goals: to apply rigorous science to overlooked conditions with a high unmet need, and in doing so make a positive difference to millions of people’s lives.